Tag: COVID-19

Pfizer Lookout For A Partner For Drug Manufacturing

Major pharmaceutical company Pfizer is on a lookout for potential contract manufacturing options. This is because Pfizer is ensuring that the Covid-19 antiviral drug can be accessed across the low- and middle-income countries including India. Through this potential manufacturing options, the company wants that there must be an easy access to Covid-19 antiviral drug among … Continue reading Pfizer Lookout For A Partner For Drug Manufacturing

Read more »

CRISPR Patent Process And Its Applicability In The Covid Era

INTRODUCTION CRISPR technology is a targeted technique that allows researchers to modify genomes with unprecedented precision, efficiency, and flexibility. This technology is at the heart of a true biotechnology revolution, with huge implications for health, agriculture, and a variety of other sectors. On October 7, 2020, Professors Emmanuelle Charpentier and Jennifer Doudna were awarded the … Continue reading CRISPR Patent Process And Its Applicability In The Covid Era

Read more »

IP Waiver and Covid-19 Vaccines

Since 2019, coronavirus hit the whole world and it is now for 2 years, we are facing this unfortunate pandemic. As of 27 October 2021, there is a total of 24.43cr cases and 49.61lakh deaths worldwide with the USA on top followed by India and Brazil. The figures are alarming but the ground situation is … Continue reading IP Waiver and Covid-19 Vaccines

Read more »

Zooming Out On Compulsory Licensing Of Covid-19 Vaccines

The unnerving bio- catastrophe, the COVID-19 pandemic has brought an array of challenges for mankind. The COVID-19 scare at the global level is posing threat to human life and the governments are deeply divided over an effort to endorse a temporary patent waiver on COVID-19 vaccines and grant of compulsory licenses. What is Compulsory Licensing? … Continue reading Zooming Out On Compulsory Licensing Of Covid-19 Vaccines

Read more »

Compulsory Licensing in India Amidst the COVID 19 Pandemic: Will India Consider it?

The COVID-19 pandemic has truly exposed the frailty of our infrastructural systems. Innovation has taken a front seat and the world is keenly awaiting the public distribution of COVID-19 vaccines which would help restore normalcy.  Among the numerous factors that were taken into consideration by global experts with respect to the COVID 19 vaccines, accessibility … Continue reading Compulsory Licensing in India Amidst the COVID 19 Pandemic: Will India Consider it?

Read more »

Premas Biotech and Oravax enter into licensing deal for commercialization of VLP injectable vaccine technology in India

Recently, Oravax Medical Inc., (“Oravax” has entered into a licensing agreement with Premas Biotech to make available for commercialization of Oravax’s virus-like particle (VLP) vaccine technology. Oravax is a joint venture between Oramed Pharmaceuticals Inc., a US-based company (the majority shareholder), and Gurugram, India-based life sciences company, Premas Biotech (“Premas”). While the terms of the … Continue reading Premas Biotech and Oravax enter into licensing deal for commercialization of VLP injectable vaccine technology in India

Read more »

Patents and Public Health

Introduction Patents and public health is the most relevant topic of discussion when the whole world is fighting against the global pandemic, Covid-19. It is no doubt that granting patent protection to a drug is important and serves many purposes, but can we put the lives of millions of people at stake in this time … Continue reading Patents and Public Health

Read more »

Covid-19 & Competition Act Of India

About Competition What does one understand by the word “Competition”? In common man’s language competition in the market would refer to rivalry between 2 entities selling similar products and/or services with the goal of achieving revenue, profit and market share. Thus it ensures that the entities involved with similar products compete on merits and not … Continue reading Covid-19 & Competition Act Of India

Read more »

Voluntary Licensing Agreements for Remdesivir

Gliead is rapidly working to fight with this outbreak of novel COVID-19. Remdesivir is a potential drug for the treatment for COVID-19. Remdesivir has formally not been approved as treatment of COVID-19. USA is using appropriate authorities for the investigation of the drug. That there are multiple clinical trials going on check safety and efficiency … Continue reading Voluntary Licensing Agreements for Remdesivir

Read more »

Covid-19 And IBC: Unfolding The Loopholes In The Recent Amendments

In the past four months, Covid-19 is the primary reason for economic instability and uncertainty for business and companies globally, Indian companies are no exception. There is no legislation in India that is left unaffected. The government has taken measures to curb the problems in order to handle the unforeseen problems that every sector of … Continue reading Covid-19 And IBC: Unfolding The Loopholes In The Recent Amendments

Read more »

Archives

  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010